StockUS listing USBIIBNASDAQHealthcareDefensive Anchor

Biogen Inc(BIIB) Stock Analysis | Healthcare

USD --+0.00%
Reward53Moderate
Risk19Low
75%Data
Thin 3% profit margin · Revenue growing 11% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 36.89Bn
Reward Ratingⓘ53 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ19 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BIIB to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Biogen Inc?

discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

AI Brief Pro

The brief on Biogen Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Biogen Inc?

discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 36.89B, and a P/E ratio of 108.0x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (53)

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
P/E Ratio108.0476
Beta0.086
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
21,186 shares
$240k
0
6-9months
0
0
9-12months
23,408 shares
$666k
13 shares
$585